Bio & Pharma
Inventage Lab, Yuhan to co-work for obesity treatment
The two companies will jointly formulate optimization and commercialize the semaglutide-based long-acting injectable IVL3021
By Jan 05, 2024 (Gmt+09:00)
1
Min read
Most Read
S.Korea's LS Materials set to boost earnings ahead of IPO process
Blackpink’s dance performance video surpasses 1.7 billion views
HD Hyundai seeks to acquire Leeyoung to prepare for shipbuilding boom
LG Chem develops material blocking battery thermal runaway
Korea Zinc, Bain Capital offer $2.4 bn share buyback vs MBK
South Korea’s Inventage Lab Inc. announced on Friday that it has signed a joint development agreement with Yuhan Corp. for a long-acting injectable for the treatment of obesity and diabetes.
Inventage Lab is developing a pipeline of differentiated long-acting injectables using its proprietary platform technology IVL-DrugFluidic.
Yuhan Corp. possesses business development capabilities and achievements in clinical development alongside marketing expertise.
Both companies anticipate mutual synergies in the field of obesity and diabetes treatment through this agreement.
Under the latest contract, Inventage Lab, leveraging its cumulative capabilities in long-acting injectable development, will handle formulation optimization, initial development, and manufacturing.
Yuhan Corp., with its excellent clinical development capabilities, will take charge of late-stage development and commercialization, jointly pursuing the maximization of product value.
Inventage Lab is conducting preclinical trials for "IVL3021," a one-month long-acting injectable based on semaglutide for obesity treatment. Recently, stable formulation research results were presented at an international conference.
Semaglutide is the active ingredient in Novo Nordisk's obesity treatment Wegovy, demonstrating a 14.9% weight loss effect over a year and efficacy in cardiovascular diseases.
Write to Ye-Na Kim at yena@hankyung.com
Inventage Lab is developing a pipeline of differentiated long-acting injectables using its proprietary platform technology IVL-DrugFluidic.
Yuhan Corp. possesses business development capabilities and achievements in clinical development alongside marketing expertise.
Both companies anticipate mutual synergies in the field of obesity and diabetes treatment through this agreement.
Under the latest contract, Inventage Lab, leveraging its cumulative capabilities in long-acting injectable development, will handle formulation optimization, initial development, and manufacturing.
Yuhan Corp., with its excellent clinical development capabilities, will take charge of late-stage development and commercialization, jointly pursuing the maximization of product value.
Inventage Lab is conducting preclinical trials for "IVL3021," a one-month long-acting injectable based on semaglutide for obesity treatment. Recently, stable formulation research results were presented at an international conference.
Semaglutide is the active ingredient in Novo Nordisk's obesity treatment Wegovy, demonstrating a 14.9% weight loss effect over a year and efficacy in cardiovascular diseases.
Write to Ye-Na Kim at yena@hankyung.com
More to Read
-
Bio & PharmaInventage Lab launches clinical trials for addiction treatment in Australia
Jan 26, 2023 (Gmt+09:00)
1 Min read
Comment 0
LOG IN